Analyzing the Release of Copeptin from the Heart in Acute Myocardial Infarction Using a Transcoronary Gradient Model

Jes-Niels Boeckel1,2,3, Jana Oppermann1, Remzi Anadol1, Stephan Fichtlscherer2, Andreas M. Zeiher1,3 & Till Keller1,3

Copeptin is the small C-terminal portion of the antidiuretic pre-proprotein of arginine vasopressin (proAVP). AVP is generally released in response to stress on the circulatory system such as an increase in plasma osmolality resulting in an antidiuretic effect1. Copeptin is released in the same amount as AVP. However AVP has only a half-life of 5–20 min in plasma compared to days for copeptin2,3. Therefore, copeptin has been established as a reliable biomarker for heart diseases as well as a predictor of mortality instead of AVP4–6.

Elevation of AVP and copeptin can be observed in a variety of pathophysiological conditions e.g. type 2 diabetes7,8, pneumonia9, acute pancreatitis10,11, sepsis12,13 but also cardiac stress and injury14–17. Besides the established biomarkers for cardiac injury like cardiac troponins, copeptin levels might provide additional information regarding circulatory stress levels and hemodynamic instability. Therefore, copeptin has shown to provide amendatory diagnostic information for early discrimination of e.g. acute myocardial infarction (AMI) in combination with cardiac troponins in most published studies14–17.

AVP is usually synthesized in the hypothalamic supraoptic (SON) and paraventricular (PVN) nuclei and released from the neurohypophysis into the circulation18. In one published study19 isolated rat hearts were put under elevated cardiovascular wall stress which led to increased levels of vasopressin on mRNA and on peptide level. Therefore, this study implies a potential release of copeptin from the heart into the circulation. Since then, evidence for a release of Vasopressin and copeptin has only been show from the hypophysis, if the heart also contributes to a release into the blood is matter of an ongoing debate.

Therefore, we analyzed a potential release from the heart by measuring the concentration of copeptin using a transcoronary gradient model (TCG) in patients with AMI.

Methods

Study cohort. Patients who underwent a coronary angiography at the University Hospital Frankfurt between October 2009 and September 2010 were enrolled as described earlier in detail20. In brief, they were classified as AMI patients in case of presence of a relevant coronary artery disease in the performed angiography and elevated cardiac troponin T (cTnT) levels and as non-AMI in case of low cTnT levels. Pre-defined exclusion criteria were known history of leukopenia, thrombocytopenia, severe hepatic disorder, severe renal dysfunction, sepsis, pancreatitis, ongoing inflammatory or malignant disease and the diagnosis of myocarditis or cardiogenic shock at presentation. The local ethics review board of the Goethe University Frankfurt (Frankfurt, Germany) approved...
the protocols, and the study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from each individual.

Sample collection and laboratory methods. Blood was simultaneously collected from the aortic bulb (AO) and the coronary venous sinus (CVS) during a standard cardiac catheterization procedure before heparin or any contrast agent was administered and before any interventional procedure was started as described previously20. The TCGs for individual biomarkers were calculated by subtracting the AO from the CVS levels. After centrifugation, plasma and serum samples were transferred to RNase/DNase-free tubes and stored at −80 °C within 1–2 hours.

Copeptin levels were measured in CVS and AO blood samples in 50 μl serum using the copeptin US assay on a KRYPTOR compact PLUS (BRAHMS Thermo Scientific) in accordance with the manufactures instructions. Measurements were carried out by experienced staff blinded to patient characteristics.

cTnT was measured using a commercially available highly sensitive assay (Roche diagnostics) at the central laboratory of the recruiting institution. As no established 99th percentile cut-off is available for cTnT measurements using CVS blood, a concentration of 100 pg/ml was used as discriminatory threshold.

Statistics. The p-values in the baseline table refer to the exact Fisher's test, t- and Wilcoxon tests for categorical, symmetric and skewed distributions, respectively. A possible association between chest pain onset time, and copeptin TCG levels were analyzed by calculation of the Spearman correlation coefficients. All analyses were carried out using the R software package version 3.1 (R Foundation for Statistical Computing, Vienna, Austria).

Results

To determine whether the heart contributes to the release of copeptin into the bloodstream in humans, we measured copeptin levels in patients suffering an AMI and in patients without AMI. A detailed characteristic of the study cohort is provided in table 1.

Levels of cTnT, as established biomarker representing myocardial ischemia, as well as copeptin were determined in samples from the aorta (AO) and the coronary venous sinus (CVS) in patients with (n = 15) and without (n = 14) the diagnosis AMI. Of those, 5 suffered a non-ST elevation myocardial infarction whereas 10 showed significant ST elevation in the electrocardiogram.

Transcoronary release of cardiac troponin T in acute myocardial infarction. In the patient group without an AMI we found a mean cTnT concentration of 4.15 pg/ml (±0.66) in AO samples, while 5.59 pg/ml (±0.74) was detected in the CVS (Fig. 1A). This resulted in a slightly positive transcoronary gradient (TCG) concentration for cTnT of 1.45 pg/ml (±0.58) (Fig. 2A). In contrast, in AMI patients we found a significantly (P < 0.001) higher cTnT AO concentrations of 337.17 pg/ml (±98.95) and of 564.47 pg/ml (±183.14) in the CVS (P < 0.001) (Fig. 1A). This resulted in a relevant positive higher TCG of 227.30 pg/ml (±96.34) (Fig. 2A) compared to non-AMI patients (P < 0.001). If restricting these analyses to AMI patients without ST elevations a comparable positive TCG of 76.10 pg/ml (±58.61) was observed.

Transcoronary gradient of copeptin. In the non-AMI group we found mean AO copeptin levels of 8.73 pmol/l (±1.67) and of 8.54 pmol/l (±1.64) in the CVS (Fig. 1B). In line with recent publications14,17, we could detect significantly (P = 0.018) increased levels of copeptin in AMI patients measured in the AO 29.78 pmol/l (±9.32) as well as a significantly (P = 0.026) increased levels in the CVS with 29.70 pmol/l (±8.85) (Fig. 1B). This difference between AMI and non-AMI patients leads to a diagnostic information of copeptin quantified by the area under the curve in the receiver operator characteristics analyses of 0.74 (0.55–0.93) for copeptin measured in the CVS and of 0.76 (0.57–0.94) if determined in AO blood.

However, no relevant release or uptake of copeptin during the transcoronary blood passage could be detected when comparing the mean TCG of patients with or without the diagnosis AMI with −0.07 and −0.18 pmol/l (P = 0.78), respectively (Fig. 2B). Considering only AMI patients without ST elevations likewise no relevant cardiac copeptin release could be observed with a TCG of 0.02 pg/ml (±0.29).

Additionally, the potential association of a transcoronary copeptin gradient and time between symptom onset and time of blood sampling was evaluated. This time interval did not show a relevant correlation with the TCG of copeptin (correlation coefficient: −0.072; p = 0.80). Furthermore, AMI patients presenting early, within 4 hours after onset of symptoms (n = 7), showed no difference in TCG of copeptin with mean of −0.185 pmol/l compared to 0.021 pmol/l (p = 0.91) as determined in patients presenting later than 4 h.

Discussion

Timely diagnosis and especially a valid early rule-out of an AMI are crucial already in the emergency department. Amendatory to the established biomarkers, which are released mainly from the heart due to myocardial injury, like cardiac troponins, copeptin has shown diagnostic value. Copeptin is increased by several disease processes besides the cardiovascular system and is therefore a more universal biomarker for severe patients’ physiology21. Within the recent years, several publications demonstrated that copeptin indeed provides additional information for risk stratification and rule-out of AMI when combined with cardiac troponins22,23.

Aside from the fact that AVP and copeptin are usually synthesized in the hypothalamic supraoptic (SON) and paraventricular (PVN) nuclei and released from the neurohypophysis into the circulation18, the potential release from the heart has been raised by evidence of AVP mRNA and protein expression in rat hearts put under elevated cardiovascular wall stress19.

Within the present study, we measured copeptin levels before the transcoronary blood passage in the AO and after the heart in the CVS draining the myocardium. In the patients that did not suffer an AMI we determined copeptin with a mean 8.72 pmol/l (±1.66) in blood taken form the AO and with 8.54 pmol/l (±1.64) in CVS
blood resembling non-diseased levels in the same magnitude as published in healthy individuals found with median of 4.3 pmol/l and of 3.2 pmol/l in females and males respectively24 and with published upper 95th percentile reference limit of 9.8 pmol/l as potential diagnostic threshold in evaluation of suspected AMI 17. Regarding the potential cardiac release of copeptin, we did not observe a positive TCG gradient suggesting a non-cardiac origin of copeptin.

In line with several recent publications we demonstrate a clear increase of copeptin in patients with AMI14,17,25 well above the mentioned cut-off with significant higher levels of copeptin in the aorta and the CVS of AMI.

Table 1. Baseline characteristics of the study cohort (n = 29). Data are presented as n (%), mean (standard error of the mean) or median (25th, 75th percentile). AMI denotes Acute Coronary Syndrome, NSTEMI denotes Non ST-elevation myocardial infarction, STEMI denotes ST-elevation myocardial infarction. Obesity was defined as body mass index of at least 30. Data is shown as percentage, mean (SEM) for troponin and copeptin and median (IQR) for chest onset time. P-values in the baseline table refer to chi square, t- and Wilcoxon tests for categorical, and continuous symmetric and skewed distributed variables, respectively.

|                          | Number of patients | AMI          | Number of patients | non-AMI      | p-value |
|--------------------------|--------------------|--------------|--------------------|--------------|---------|
| Male gender              | 15                 | 12/15 (80%)  | 14                 | 13/14 (93%)  | 0.598   |
| Age (years), mean (SD)   | 15                 | 62.1 (10.9)  | 14                 | 56.7 (9.8)   | 0.174   |
| NSTEMI                   | 5/15 (33%)         |              | 14                 | 10/14 (71%)  |         |
| STEMI                    | 10/15 (66%)        |              |                    |              |         |

Cardiovascular risk factors

|                          | Number of patients | AMI          | Number of patients | non-AMI      | p-value |
|--------------------------|--------------------|--------------|--------------------|--------------|---------|
| Hypertension             | 15                 | 10/15 (67%)  | 14                 | 10/14 (71%)  | 1       |
| Hyperlipidemia           | 14                 | 1/14 (7%)    | 14                 | 1/14 (7%)    | 1       |
| Diabetes mellitus        | 15                 | 4/15 (27%)   | 14                 | 5/14 (36%)   | 0.561   |
| Active smoker            | 14                 | 6/14 (43%)   | 14                 | 8/14 (57%)   | 0.705   |
| Obesity                  | 10                 | 4/10 (40%)   | 14                 | 7/14 (50%)   | 0.697   |
| Family history           | 13                 | 1/13 (8%)    | 13                 | 1/13 (8%)    | 1       |
| Ejection fraction        | 15/12              | 44 ± 10      | 14/12              | 51 ± 13      | 0.19    |

Laboratory parameters on admission

|                          | Number of patients | AMI          | Number of patients | non-AMI      | p-value |
|--------------------------|--------------------|--------------|--------------------|--------------|---------|
| Troponin T - CVS (pg/mL) | 15                 | 564.47 ± 183.14 | 14                | 5.59 ± 0.74 | <0.001 |
| Troponin T - AO (pg/mL)  | 15                 | 337.17 ± 98.95 | 14                | 4.15 ± 0.66 | <0.001 |
| Troponin T - TCG (pg/mL) | 15                 | 227.2 ± 96.3  | 14                | 1.45 ± 0.58 | <0.001 |
| Copeptin - CVS (pmol/L)  | 15                 | 29.70 ± 8.85  | 14                | 8.54 ± 1.64 | 0.018   |
| Copeptin - AO (pmol/L)   | 15                 | 29.78 ± 9.32  | 14                | 8.73 ± 1.67 | 0.026   |
| Copeptin - TCG (pmol/L)  | 15                 | −0.07 ± −0.86  | 14                | −0.18 ± −0.32 | 0.78   |
| NT-proBNP - CVS (pg/mL)  | 15                 | 959.04 ± 227.45 | 14              | 120.20 ± 23.63 | 0.02 |
| NT-proBNP - AO (pg/mL)   | 15                 | 767.95 ± 233.76 | 14             | 90.27 ± 23.50 | 0.014 |
| NT-proBNP - TCG (pg/mL)  | 15                 | 191.09 ± 80.74 | 14               | 29.92 ± 7.81 | 0.354 |

Clinical variables

|                          | Number of patients | AMI          | Number of patients | non-AMI      | p-value |
|--------------------------|--------------------|--------------|--------------------|--------------|---------|
| Chest pain onset time [h], median (IQR) | 15 | 5.0 (2.5, 9) |                    |              |         |

Figure 1. (a) Level of aortic and CVS cardiac troponin T, (b) copeptin levels in patients with acute myocardial infarction (AMI; n = 15) compared to patients without AMI (non-AMI; n = 14).
patients compared to those without AMI that’s does not originate directly from the myocardium. As expected, we saw a profound positive and significant TCG for cTnT in samples from AMI patients indicating a progressive release from the heart muscle, in contrast to copeptin levels before and after the heart remained unchanged.

However, copeptin and cTnT have different release kinetics after onset of chest pain. Patients with myocardial infarction might even have highest copeptin levels already at the time of admission to the emergency department. Therefore, the levels of copeptin in our study might already been equalized by saturation of the aortic and venous system. In such case, a release of copeptin resulting in a positive TCG would no longer be detectable when comparing AO and CVS copeptin levels. Given that the median time since onset of chest pain in the present cohort was 5 h (25th percentile 2.5 h, 75th percentile 9 h), quite comparable to the published results, and furthermore no relevant association of copeptin TCG with chest pain onset time was observed in our cohort, this seems not very likely. Moreover, in a human model for myocardial infarction in patients undergoing transcoronary ablation of septal hypertrophy, a significant increase of copeptin was seen as early as 30 min after induction of myocardial infarction lasting for 240–480 min putting our evaluated patients in the relevant timeframe.

One has to acknowledge the aspect, that we measured copeptin as surrogate marker for AVP. Still, given the assumed equimolar release of AVP and copeptin and the preferable preanalytics of copeptin this should not limit the general information on transcoronary release as reported.

To conclude, in line with previous reports we found a significant increase of copeptin in patients suffering an AMI supporting the use as diagnostic biomarker. Using a TCG model we could not detect a relevant direct cardiac release of copeptin into the coronary circulation in AMI patients. In summary even if there is an expression of AVP and copeptin in the human heart, the present study indicates that a direct release of copeptin is not detectable from the human heart in acute myocardial infarction.

References
1. Tsutamoto, T. et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. *Circulation* **96**, 509–16 (1997).
2. Morgenthaler, N. G., Struck, J., Alonso, C. & Bergmann, A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. *Clin. Chem.* **52**, 112–9 (2006).
3. Czaczkes, J. W., Kleeman, C. R. & Koenig, M. Physiologic studies of antidiuretic hormone by its direct measurement in human plasma. *J. Clin. Invest.* **43**, 1625–40 (1964).
4. Yalta, K. et al. Copeptin (C-terminal provasopressin): a promising marker of arrhythmogenesis in arrhythmia prone subjects? *Int. J. Cardiol.* **148**, 105 (2011).
5. Stoiser, B. et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. *Eur. J. Clin. Invest.* **36**, 771–8 (2006).
6. Maisel, A. et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. *Circ. Heart Fail.* **4**, 613–20 (2011).
7. Bar-Shalom, D. et al. Plasma copeptin as marker of cardiovascular disease in asymptomatic type 2 diabetes patients. *Diab. Vasc. Dis. Res.* **11**, 448–50 (2014).
8. Velho, G. et al. Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. *Diabetes Care* **36**, 3639–3645 (2013).
9. Seligman, R., Papassotiriou, J., Morgenthaler, N. G., Meisner, M. & Teixeira, P. J. Z. Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. *Crit. Care* **12**, R11 (2008).
10. Sang, G. et al. Plasma copeptin levels are associated with prognosis of severe acute pancreatitis. *Peptides* **51**, 4–8 (2014).
11. Isman, F. K. et al. Copeptin is a predictive biomarker of severity in acute pancreatitis. *Am J Emerg Med.* (2013). doi: 10.1016/j.ajem.2012.12.016
12. Katan, M. & Christ-Crain, M. The stress hormone copeptin: a new prognostic biomarker in acute illness. *Swiss Med. Wkly. Off. J. Swiss Soc. Infect. Dis. Swiss Soc. Intern. Med. Swiss Soc. Pneumol.* **140**, 1–6 (2010).

Figure 2. (a) Level of transcoronary cardiac troponin T and (b) copeptin gradients in patients with acute myocardial infarction (AMI; n = 15) compared to patients without AMI (non-AMI; n = 14). Data is shown as mean ± SEM. Statistical differences between groups were analysed using the Wilcoxon test.

\[ P < 0.001 \]

\[ P = 0.78 \]
13. Zhang, Q., Dong, G., Zhao, X., Wang, M. & Li, C.-S. Prognostic significance of hypothalamic-pituitary-adrenal axis hormones in early sepsis: a study performed in the emergency department. *Intensive Care Med.* **40**, 1499–508 (2014).
14. Reichlin, T. *et al.* Incremental value of copeptin for rapid rule out of acute myocardial infarction. *J. Am. Coll. Cardiol.* **54**, 60–8 (2009).
15. Maisel, A. *et al.* Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial Infarction). *J. Am. Coll. Cardiol.* **62**, 150–60 (2013).
16. Karakas, M. *et al.* Copeptin does not add diagnostic information to high-sensitivity troponint in low- to intermediate-risk patients with acute chest pain: Results from the Rule Out Myocardial Infarction by Computed Tomography (ROMICAT) study. *Clin. Chem.* **57**, 1137–1145 (2011).
17. Keller, T. *et al.* Copeptin improves early diagnosis of acute myocardial infarction. *J. Am. Coll. Cardiol.* **55**, 2096–106 (2010).
18. Arima, H. & Aguilera, G. Vasopressin and oxytocin neurones of hypothalamic supraoptic and paraventricular nuclei co-express mRNA for Type-1 and Type-2 corticotropin-releasing hormone receptors. *J. Neuroendocrinol.* **12**, 833–42 (2000).
19. Hupf, H., Grimm, D., Rieger, G. A. & Schunkert, H. Evidence for a vasopressin system in the rat heart. *Circ. Res.* **84**, 365–70 (1999).
20. De Rosa, S. *et al.* Transcoronary concentration gradients of circulating microRNAs. *Circulation* **124**, 1936–44 (2011).
21. Nickel, C. H., Bingisser, R. & Morgenthaler, N. G. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. *BMC Med.* **10**, 7 (2012).
22. Rasko, K. *et al.* Release kinetics of copeptin in patients undergoing transcoronary ablation of septal hypertrophy. *Clin. Chem.* **57**, 1137–1145 (2011).
23. Lipinski, M. J. *et al.* A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction. *Am. J. Cardiol.* **113**, 1581–91 (2014).
24. Bhandari, S. S. *et al.* Gender and renal function influence plasma levels of copeptin in healthy individuals. *Clin. Sci. (Lond)*. **116**, 257–63 (2009).
25. Giavarina, D. *et al.* Copeptin and high sensitive troponin for a rapid rule out of acute myocardial infarction? *Clin. Lab.* **57**, 725–30 (2011).
26. Liebetrau, C. *et al.* Release kinetics of copeptin in patients undergoing transcoronary ablation of septal hypertrophy. *Clin. Chem.* **59**, 566–9 (2013).

Acknowledgements

We thank Marga Müller-Adorgan, Tino Roexe and Katrin Wetekam for technical assistance and Lars Palapies for statistical advice. The study was supported by the Deutsche Forschungsgemeinschaft (SFB834, Project B1) to S.F., the German Center of Cardiovascular Research (DZHK) by the BMBF to A.M.Z. and Brahms Thermofischer via an unrestricted grant. TK received honoraria from Brahms Thermo Fisher for consultancy and speaker honoraria.

Author Contributions

J.-N.B. and T.K. wrote the main manuscript text and analyzed data. A.M.Z. and S.F. took samples and acquired patients. J.O. and R.A. analyzed data. All authors reviewed the manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Boeckel, J.-N. *et al.* Analyzing the Release of Copeptin from the Heart in Acute Myocardial Infarction Using a Transcoronary Gradient Model. *Sci. Rep.* **6**, 20812; doi: 10.1038/srep20812 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/